19 After a median follow-up of 42.5 months, there was a clear trend for apalutamide to improve OS relative to placebo in Asian patients, as indicated by a 32% reduction in the risk of death, despite crossover of 42.7% of the placebo ITT population to open-label apalutamide after study unblinding.
← all excerpts
Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial.
1
—
—